October 30th, 2009
Wolcott RD et al. – The polymicrobial nature of VLU and previous research on diabetic foot ulcers and surgical site infections suggest that the future of therapy for such wounds lies in the core of the logical and proven multiple concurrent strategy approach, which has been termed “biofilm–based wound care” and the use of individualized therapeutics rather than in a single treatment modality. read more
October 30th, 2009
Marcelli D et al. – End–stage renal disease patients should be included in first ranks of the priority list for the influenza A(H1N1)v vaccine, as already advocated by some healthcare authorities.
read more
October 29th, 2009
Lautenbach E et al. – Many A. baumannii isolates exhibit imipenem resistance, which is strongly associated with prior use of carbapenems. Given the high mortality rate associated with A. baumannii infection or colonization, interventions to curb further emergence of cases of IRAB infection and strategies to optimize therapy are needed.
read more
October 26th, 2009
Cimsit M et al. – HBOT is used as either a primary or adjunctive treatment in the management of infections such as gas gangrene, necrotizing fasciitis, diabetic foot infections, refractory osteomyelitis, neurosurgical infections and fungal infections. HBOT acts as a bactericidal/bacteriostatic agent against anerobic bacteria by increasing the formation of free oxygen radicals. HBOT restores the bacterial–killing capacity of leukocytes in hypoxic wounds by increasing tissue oxygen tensions. read more
